Green Cross Blood Product 'Aliglo' Initial Shipment to the United States Dispatched

GC Green Cross has started shipments of Aliglo, a blood product approved by the U.S. Food and Drug Administration (FDA), to the United States.

Blood product 'Aliglo' is being shipped from GC Green Cross Ochang Plant in Ochang, Chungbuk.
[Photo by GC Green Cross]

GC Green Cross announced on the 8th that it has completed the initial shipment of Aliglo for sale in the U.S. The shipped quantity is expected to be delivered to specialty pharmacies through logistics warehouses and distributors within the U.S., enabling actual prescriptions to begin by mid-month.

Aliglo is an immunoglobulin blood product that received FDA approval in December last year. It is a 10% intravenous immunoglobulin preparation used to treat primary immunodeficiency, also known as congenital immunodeficiency. After obtaining product approval, the company has been preparing for commercialization by establishing a direct sales system centered on its U.S. subsidiary, GC Biopharma USA, and engaging in activities such as PBM contracts for listing Aliglo in formularies of major prescription benefit managers (PBMs) and securing specialty pharmacies.

In particular, on the 1st, the company signed a contract for listing Aliglo in the formulary with one of the so-called "Big 3 PBMs," which dominate about 80% of the U.S. PBM market. Additionally, contracts have been completed with well-known specialty pharmacies and distributors targeted as key distribution channels, and the company plans to actively secure additional channels to further penetrate the market.

This content was produced with the assistance of AI translation services.